As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...
Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...
2024 Germany's Merck KGaA agreed to sell its pigments unit to China's Global New Material International (GNMI) for 665 million euros ($721.46 million), the German diversified group said on Thursday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback